Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Summary

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not known if a transplant if beneficial.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Anaplastic Large Cell Lymphoma, ALK-Negative
• Follicular Helper T-Cell Lymphoma
• Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
• Peripheral T-Cell Lymphoma, Not Otherwise Specified

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Eastern Cooperative Oncology Group

Last updated on ClinicalTrials.gov

September 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites